Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tafamidis

FDA-approved product (capsule, oral), marketed as Vyndamax, Vyndaqel.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Tafamidis
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • AL amyloidosis
  • Amyloidosis
  • Cardiomyopathy

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other nervous system drugs
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli27.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae15.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis35.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tafamidis in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tafamidis with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

    NCT02791230 · start 2016-06-13

    Registered record
    Registry ID
    NCT02791230
    Conditions
    Transthyretin (TTR) Amyloid Cardiomyopathy
    Interventions
    Tafamidis
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-06-13
    Completion
    2023-11-02
    Enrolment
    1,733

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTransthyretin (TTR) Amyloid Cardiomyopathy
    InterventionTafamidis
    PhasePhase 3
    Registry statusCompleted

  • A Study Comparing Amounts of Tafamidis (PF-06291826) in the Blood Without Food in Healthy Volunteers

    NCT02746926 · start 2016-04-29

    Registered record
    Registry ID
    NCT02746926
    Conditions
    Healthy
    Interventions
    tafamidis
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-04-29
    Completion
    2016-07-15
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventiontafamidis
    PhasePhase 1
    Registry statusCompleted

  • A Study Comparing Amounts of Tafamidis In The Blood Without Food

    NCT02697864 · start 2016-04

    Registered record
    Registry ID
    NCT02697864
    Conditions
    Healthy
    Interventions
    tafamidis
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-04
    Completion
    2016-06
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventiontafamidis
    PhasePhase 1
    Registry statusCompleted

  • A Study Comparing Amounts of Tafamidis In The Blood With Or Without Food

    NCT02534740 · start 2015-09

    Registered record
    Registry ID
    NCT02534740
    Conditions
    Healthy
    Interventions
    tafamidis; tafamidis; tafamidis
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-09
    Completion
    2015-12
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventiontafamidis; tafamidis; tafamidis
    PhasePhase 1
    Registry statusCompleted

  • A Study Comparing The Amounts of Tafamidis In The Blood With Or Without Food

    NCT02406560 · start 2015-04

    Registered record
    Registry ID
    NCT02406560
    Conditions
    Healthy Volunteers
    Interventions
    tafamidis; tafamidis; tafamidis
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-04
    Completion
    2015-06
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    Interventiontafamidis; tafamidis; tafamidis
    PhasePhase 1
    Registry statusCompleted

  • A Bioequivalence Study Comparing Two Different Tafamidis Formulations

    NCT02217813 · start 2014-10

    Registered record
    Registry ID
    NCT02217813
    Conditions
    Healthy Volunteers
    Interventions
    Tafamidis; Tafamidis
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-10
    Completion
    2014-11
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionTafamidis; Tafamidis
    PhasePhase 1
    Registry statusCompleted

  • Vyndaqel Drug Use Investigation (Regulatory Post Marketing Commitment Plan)

    NCT02146378 · start 2014-01-10

    Registered record
    Registry ID
    NCT02146378
    Conditions
    Transthyretin Familial Amyloid Polyneuropathy
    Interventions
    Vyndaqel
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-01-10
    Completion
    2023-03-10
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTransthyretin Familial Amyloid Polyneuropathy
    InterventionVyndaqel
    PhaseNot recorded
    Registry statusCompleted

  • Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy

    NCT01994889 · start 2013-12-09

    Registered record
    Registry ID
    NCT01994889
    Conditions
    Transthyretin (TTR) Amyloid Cardiomyopathy
    Interventions
    Tafamidis; Tafamidis; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-12-09
    Completion
    2018-02-07
    Enrolment
    441

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTransthyretin (TTR) Amyloid Cardiomyopathy
    InterventionTafamidis; Tafamidis; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study To Determine Any Effect Of Tafamidis On Electrocardiographic Intervals, Specifically The Rate Corrected QT Interval (QTc)

    NCT01775761 · start 2013-01

    Registered record
    Registry ID
    NCT01775761
    Conditions
    TTR Cardiomyopathy
    Interventions
    Period 1; Period 2; Period 3
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-01
    Completion
    2013-04
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTTR Cardiomyopathy
    InterventionPeriod 1; Period 2; Period 3
    PhasePhase 1
    Registry statusCompleted

  • Safety And Pharmacokinetic Assessment Of Orally Administered Tafamidis In Healthy Volunteers

    NCT01655511 · start 2012-07

    Registered record
    Registry ID
    NCT01655511
    Conditions
    TTR Cardiomyopathy
    Interventions
    Tafamidis; Tafamidis; Tafamidis
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-07
    Completion
    2012-09
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTTR Cardiomyopathy
    InterventionTafamidis; Tafamidis; Tafamidis
    PhasePhase 1
    Registry statusCompleted

  • The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin

    NCT01435655 · start 2011-11

    Registered record
    Registry ID
    NCT01435655
    Conditions
    Transthyretin Familial Amyloid Polyneuropathy
    Interventions
    tafamidis
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-11
    Completion
    2014-02
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTransthyretin Familial Amyloid Polyneuropathy
    Interventiontafamidis
    PhasePhase 3
    Registry statusCompleted

  • Study Of Single Doses Of PF-06291826 (Tafamidis) In Japanese And Western Subjects

    NCT01369836 · start 2011-07

    Registered record
    Registry ID
    NCT01369836
    Conditions
    Healthy
    Interventions
    Tafamidis meglumin; Tafamidis meglumin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-07
    Completion
    2011-08
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTafamidis meglumin; Tafamidis meglumin; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetics Of Orally Administered Fx-1006A In Subjects With Hepatic Dysfunction

    NCT01358565 · start 2010-11

    Registered record
    Registry ID
    NCT01358565
    Conditions
    Mild Hepatic Dysfunction; Moderate Hepatic Dysfunction
    Interventions
    Fx-1006A; Fx-1006A
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-11
    Completion
    2011-04
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMild Hepatic Dysfunction; Moderate Hepatic Dysfunction
    InterventionFx-1006A; Fx-1006A
    PhasePhase 1
    Registry statusCompleted

  • Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy

    NCT00935012 · start 2009-09-30

    Registered record
    Registry ID
    NCT00935012
    Conditions
    ATTR-CM; TTR-CM
    Interventions
    tafamidis
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-09-30
    Completion
    2019-11-20
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionATTR-CM; TTR-CM
    Interventiontafamidis
    PhasePhase 3
    Registry statusCompleted

  • Safety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin Amyloidosis

    NCT00925002 · start 2009-08-05

    Registered record
    Registry ID
    NCT00925002
    Conditions
    ATTR-PN
    Interventions
    Tafamidis
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-08-05
    Completion
    2020-07-08
    Enrolment
    93

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionATTR-PN
    InterventionTafamidis
    PhasePhase 3
    Registry statusCompleted